TERAVOLT Study Identifies 7 Factors Associated with COVID-19 Mortality in Thoracic Cancer

Article

The TERAVOLT study identified 7 factors associated with increased mortality risk for patients with thoracic malignancies who have contracted COVID-19.

Seven significant determinates of mortality have been identified for patients with thoracic malignancies who have contracted COVID-19, according to results from the TERAVOLT study which were published in the Journal of Thoracic Oncology.1

Poor ECOG-performance status had the strongest association with negative COVID-19 outcomes (OR, 2.47; 95% CI, 1.87-3.26), with other factors including neutrophil count (OR, 2.46; 95% CI, 1.76-3.44), serum procalcitonin (OR, 2.37; 95% CI, 1.64-3.43), development of pneumonia (OR, 1.95; 95% CI, 1.48-2.58), c-reactive protein (OR, 1.90; 95% CI, 1.43-2.51), tumor stage at COVID-19 diagnosis (OR, 1.97; 95% CI, 1.46-2.66) and age (OR, 1.71; 95% CI, 1.29-2.26).

“Despite the ongoing efforts including immunization campaigns and increased capacity, SARS-CoV-2 will still impact the continuity of care of patients with cancer, at least to a certain extent. Against the evolving scenario, we provided a comprehensive and powered prognostication system that can be a useful tool for clinicians.” Alessio Cortellini, MD, a medical oncologist and clinical scientist from the Imperial College London, said in a press release.2

A total of 1591 patients were enrolled into the database between March 2020 and April 2021 and 1491 were included in the analysis.

Laboratory confirmed COVID-19 infection was identified in 1432 patients, and 59 patients were diagnosed based on radiological or clinical findings. Investigators reported that 57.3% of patients were male, 72.2% were White, and 77.8% were former and current smokers. The median age for patients was 67 years, and 57.3% of patients were 65 years or older.

Among the patients included in the study, most had 1 comorbidity (82.3%), such as hypertension (48.0%), chronic obstructive pulmonary disease (24.5%), diabetes (19.3%), and ischemic heart disease (13.1%). Moreover, most patients were taking concomitant non-cancer related medications upon bring diagnosed with COVID-19 (73.4%). Prior to the COVID-19 diagnosis, 13.0% of patients were on corticosteroids.

The most common tumor types were non–small cell lung cancer (79.7%), small cell lung cancer (12.4%), and other thoracic malignancies (7.9%). At the time of COVID-19 diagnosis, 67.8% of patients had stage IV disease, 71.9% had an ECOG-performance status of 0 or 1, 64.5% had received antineoplastic treatment within 3 months of the diagnosis, and 38.8% had chemotherapy alone.

Therapy for patients with COVID-19 included anticoagulation agents (37.2%), antibiotics (48.7%), antivirals (18.9%), antifungals (2.6%), corticosteroids (33.4%), interleukin-6 inhibitors (3.1%), and antimalarials (16.4%). During the mean observation period of 42 days, 361 events were reported that translated to an all-cause fatality rate was 24.2%.

A total of 73 variables were considered in the cluster analysis, with significant associations with outcomes identified in 3 demographic , 5 comorbidity , 3 concomitant medication, 3 oncological feature, 6 full blood count information, 17 general biochemistry, 2 respiratory function, and 7 radiological finding variables.

“Currently, this analysis did not look at the impact of COVD-19 vaccination. The TERAVOLT database was recently updated to capture information about vaccination status, as well as information about the specific variants. A separate analysis will be performed with the new data.” Jennifer G. Whisenant, PhD, a research assistant professor of medicine at Vanderbilt University, concluded.

References

1. Whisenant J, Baena J, Cortellini A, et al. A definitive prognostication system for patients with thoracic malignancies diagnosed with COVID-19: an update from the TERAVOLT registry. J Thorac Oncol. Published online February 1, 2022. doi:10.1016/j.jtho.2021.12.015

2. TERAVOLT study identifies seven factors that increase mortality risk for patients with COVID-19. News Release. International Association for the Study of Lung Cancer. February 1, 2022. Accessed February 1, 2022. https://bit.ly/3ANKRJh

Recent Videos
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
Related Content